Our Story
Invictus Therapeutics is creating a range of assets originating from research conducted in the lab of Michel Weiss, MD, PhD, MBA. These assets have been under development for more than ten years across different organizations and aim to meet the unmet medical needs of insulin-dependent diabetic patients.
Since its inception, Invictus has brought together a skilled team of scientists, drug developers, physicians, and manufacturing experts to transition these promising assets from the laboratory to clinical settings.
Why Insulin?
Despite the complex, maturing market for insulin there is still a significant unmet need for an ultra-rapid, concentrated, stable insulin to support next generation insulin pumps.
Our lead candidate is a novel insulin analog designed to improve the lives of insulin pump users by addressing each of these pain points.
​
Additional assets include additional ultra-stable insulins and miniaturized pump technology - all designed to improve the growing number of insulin dependent diabetics across the world.
Lead Candidate
Best-in-class pharmacokinetics
Stable monomeric formulation up to 10x standard insulin
Stable at room temperature
(30 °C / 86 °F) for at least a year
Insulin Innovation Leaders
At Invictus Therapeutics, we are at the forefront of insulin technology, creating novel, ultra-rapid, concentrated, room temperature stable insulin analogs to improve the lives of insulin pump users.